









Markets
/
Stocks
/
nasdaq-oric
/

Oric Pharmaceuticals Inc

ORIC

12.407USD

-0.283-2.23%

Market hours （ET）Quotes delayed by 15 min

1.07BMarket Cap

LossP/E TTM



Oric Pharmaceuticals Inc

12.407

-0.283-2.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Oric Pharmaceuticals Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Oric Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

186 / 501

Overall Ranking

329 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

18.400

Target Price

+39.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Oric Pharmaceuticals Inc Highlights

StrengthsRisks

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -7.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 95.35M shares, increasing 8.15% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 6.57M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.02.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Oric Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.16, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -7.07, which is -85.05% below the recent high of -1.06 and -15.87% above the recent low of -8.19.

Score

Industry at a Glance

Previous score

6.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 186/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.17, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Oric Pharmaceuticals Inc is 19.50, with a high of 25.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.17

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

18.400

Target Price

+45.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Oric Pharmaceuticals Inc

ORIC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.02, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.18 and the support level at 11.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.53

Change

1.49

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.208

Neutral

RSI(14)

50.274

Neutral

STOCH(KDJ)(9,3,3)

57.805

Neutral

ATR(14)

0.771

Low Volatility

CCI(14)

-34.066

Neutral

Williams %R

60.146

Sell

TRIX(12,20)

0.377

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

13.110

Sell

MA10

12.915

Sell

MA20

13.237

Sell

MA50

11.811

Buy

MA100

11.050

Buy

MA200

9.188

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 98.17%, representing a quarter-over-quarter decrease of 10.87%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 6.57M shares, representing 6.77% of shares outstanding, with 7.77% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nextech Invest, Ltd.

7.16M

+35.51%

EcoR1 Capital, LLC

6.73M

+315.81%

VR Adviser, LLC

6.60M

Viking Global Investors LP

Star Investors

6.57M

Pfizer Inc

5.38M

SR One Capital Management, LP

4.62M

+2.22%

New Enterprise Associates (NEA)

4.12M

+87.59%

Alkeon Capital Management LLC

3.75M

+12.25%

The Column Group LP

3.54M

BlackRock Institutional Trust Company, N.A.

3.43M

-22.06%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.65. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.